Vol 7, No 3 - PHA Online University

More documents

Recommendations

Info

64. Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferatoractivated receptor (PPAR) alpha and PPARbetaq/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003;92:518-524. 65. Tu N, Chen H, Winnikes U, et al. Molecular cloning and functional characterization of the promoter region of the human uncoupling protein-2 gene. I. 1999;265:326-334. 66. Roussel D, Chainier F, Rouanet J, Barre H. Increase in the adenine nucleotide translocase content of duckling subsarcolemmal mitochondria during cold acclimation. I. 2000;477:141-144. 67. Skulachev VP. Anion carriers in fatty acid-mediated physiological uncoupling. J Bioenerg Biomembr. 1999;31:431-445. 68. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790. 69. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001;276:25096-25100. 70. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5:561-568. 71. Evans J L, Goldfine I D, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and b-cell dysfunction? Diabetes. 2003;52:1-8. 72. Rosen P, Du X, Sui GZ. Molecular mechanisms of endothelial dysfunction in the diabetic heart. Adv Exp Med Biol. 2001;498:75-86. 73. Marra G, Cotroneo P, Pitocco D, et al. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care. 2002;25:370-375. 74. Van Dam PS, Van Asbeck, BS, Erkelens DW, Marx JJ, Gispen WH, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev. 1995;11:181-192. 75. Kristal BS, Jackson CT, Chung HY, Matsuda M, Nguyen HD, Yu,BP. Defects at center P underlie diabetes-associated mitochondrial dysfunction. Free Radical Biol Med. 1997;22:823-833. 76. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest. 1996;97:1422-1428. 77. Lashin OM, Szweda PA, Szweda LI, Romani AM. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radical Biol Med. 2006;40:886-896. 78. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes. 2004;53:1336- 1343. 79. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes. 2006;55:798-805. 80. Shen X, Zheng S, Thongboonkerd V, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab. 2004;287:E896-E905. 81. Santos DL, Palmeira CM, Seica R, et al. Diabetes and mitochondrial oxidative stress: a study using heart mitochondria from the diabetic Goto-Kakizaki rat. Mol Cell Biochem. 2003;246:163-170. 82. Conti M, Renaud IM, Poirier B, et al. High levels of myocardial antioxidant defense in aging nondiabetic normotensive Zucker obese rats. Am J Physiol Regul Integr Comp Physiol. 2004;286:R793-R800. 83. Vincent HK, Powers SK, Stewart DJ, Shanely RA, Demirel H, Naito H. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Metab Disord. 1999;23:67-74. 84. Bugger H, Boudina S, Hu XX, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes. 2008;57: 2924-232. 85. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol. 2002;34:1259-1271. 86. Bouchard RA, Bose D. Influence of experimental diabetes on sarcoplasmic reticulum function in rat ventricular muscle. Am J Physiol. 1991;260: H341-H354. 87. Lagadic-Gossmann D, Buckler KJ, Le Prigent K, Feuvray D. Altered Ca2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol. 1996;270:H1529-H1537. 88. Penpargkul S, Fein F, Sonnenblick EH, Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13: 303-309. 89. Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS. Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes. 2001;50:2133-2138. 90. Russ M, Reinauer H, Eckel J. Diabetes-induced decrease in the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in adult rat cardiomyocytes. Biochem Biophys Res Commun. 1991;178:906-912. 91. Zhong Y, Ahmed S, Grupp IL, Matlib MA. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol. 2001;281:H1137-H1147. 92. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166-1171. 93. Vetter R, Rehfeld U, Reissfelder C, et al. Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J. 2002;16:1657-1659. 94. Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest. 2002;109:629-639. 95. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285: H1261-H1269. 96. McQueen AP, Zhang D, Hu P, et al. Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density. J Mol Cell Cardiol. 2005;39:882-892. 336 Advances in Pulmonary Hypertension
Continuing Medical Education Section Specialized Centers of Clinically Oriented Research Programs in Pulmonary Hypertension Reported Progress at the PHA Scientific Sessions Karen A. Fagan, MD, Guest Editor University of South Alabama College of Medicine Mobile, Alabama Recently, the National Heart, Lung, and Blood Institute awarded 2 Specialized Centers of Clinically Oriented Research (SCCOR) program grants in pulmonary hypertension. The SCCOR program requires clinical and basic scientists with a broad range of skills to work together on a unified theme, with special emphasis on clinically relevant research. The goal of the SCCOR program is to encourage multidisciplinary research on clinically relevant problems to allow basic science findings to be more rapidly applied to clinical situations. It is expected that over 50% of the funded research is clinical and interactions between clinical and basic scientists are expected to strengthen the research, enhance the translation of fundamental research findings to the clinical setting, and identify new research directions. In addition, each SCCOR project must have a defined organizational and administrative structure to enhance and enable interactions between investigators to increase the rate of translation of basic research findings to clinical applications. At the recent Scientific Sessions at the Pulmonary Hypertension Association 8 th International Conference, the principal investigators for the 2 SCCOR programs in pulmonary hypertension—Dr Paul Hassoun from Johns Hopkins University and Dr Kurt Stenmark from the University of Colorado Denver School of Medicine, reported on progress made in each of their research programs. These are summarized in the following reports. National Heart Lung and Blood Institute Hopkins Specialized Center in Clinical Oriented Research (SCCOR): Molecular Determinants of Pulmonary Arterial Hypertension Paul M. Hassoun, MD Professor of Medicine and Director of the Pulmonary Hypertension Program Division of Pulmonary and Critical Care Medicine Johns Hopkins University, School of Medicine Baltimore, MD Paul M. Hassoun, MD SCCOR Investigators: Paul M. Hassoun: overall Principal Investigator, Project 1 leader and administrative core leader; Hunter C. Champion: Project 2 leader; Fredrick Wigley: Project 3 leader; Roger A. Johns: Project 4 leader; Michael Crow: Project 5 leader; Noah Lechtzin: data management and statistics; Allen Myers: pathology core; Kathleen C. Barnes: genetics/genomics core; Jennifer van Eyk: proteomics core; and Jens Vogel-Claussen: imaging core. Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with the spectrum of scleroderma-related diseases. In addition, recent large clinical trials of PAH suggest that patients with scleroderma-related PAH have increased mortality and a significantly poorer response to therapy compared with patients who have idiopathic PAH. Although the reason for this discrepancy remains unclear, we hypothesized for this SCCOR that the overall worse outcome in scleroderma-related PAH is related to more severe structural changes involving the pulmonary vasculature (PV) and the right ventricle (RV), resulting in marked RV- PV dysfunction. Therefore, this SCCOR project is focused on understanding the complex PV and RV remodeling, resulting RV- PV uncoupling, and their crucial impact on morbidity and mortality in PAH. In this SCCOR, we use scleroderma-related PAH as a clinical paradigm, contrasting it to idiopathic PAH, because of its particular severity, lack of response to available PAH therapy, and potential underlying genetic factors that dictate outcome. Because of the extensive expertise of our team in molecular and diagnostic pulmonary medicine and cardiology, we have the unique opportunity to not only characterize RV-PV responses in scleroderma-related PAH with increased sensitivity and clarity, but to also identify new molecular targets for potential therapy using state of the art imaging and genomic and proteomic technology. Relying on novel imaging systems and molecular tools, we proposed to conduct rigorous phenotypic characterization of patients who have scleroderma-related PAH. Our focus on animal models provides us with additional candidate genes and proteins for characterization and targeting in human studies. We have the opportunity to validate the clinical importance of these genes in a large cohort of well-phenotyped patients with PAH, using functional genomics and proteomic approaches with characterization of potentially important polymorphisms. We hope Advances in Pulmonary Hypertension 337
Page 1 and 2: Advances in Pulmonary Hypertension
Page 3 and 4: Editorial Advisory Board Editor-in-
Page 7: SECOND WIND IN PAH
Page 10 and 11: FLOLAN ® (epoprostenol sodium) for
Page 12 and 13: REMODULIN ® (treprostinil sodium)
Page 16 and 17: Continuing Medical Education Sectio
Page 18 and 19: mal metabolism, some electrons leak
Page 22 and 23: Survival probablility (%) 13 12 11
Page 24 and 25: velopment may reveal novel targets
Page 26 and 27: lent correlation between impedance
Page 28 and 29: a Figure. (a) Schematic showing the
Page 30 and 31: Continuing Medical Education Sectio
Page 32 and 33: Conclusion Although it is not clear
Page 34 and 35: Connective Tissue Disease-Associate
Page 36 and 37: ACCP Update and New Treatments for
Page 38 and 39: the real cause of most morbidity an
Page 40 and 41: In the treatment of pulmonary arter
Page 42 and 43: LETAIRIS® (ambrisentan) 5 mg and 1
Page 44 and 45: Reference: 1. Badesch DB, Abman SH,
Page 46 and 47: Use of TRACLEER ® requires attenti
Page 48: Program Announcement: New Applicati

Vol 7, No 3 - PHA Online University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?